ImmuPharma (LON:IMM) Stock Price Up 17.2% - Here's Why

Key Points

• ImmuPharma's stock experienced a significant increase of 17.2%, rising to GBX 13.04 during Wednesday's trading session, a notable jump from its previous close of GBX 11.13.
• Over 47 million shares exchanged hands, representing a 514% increase in trading volume compared to the average session.
• The company reported a negative P/E ratio of -1,483.15 and is projected to have an EPS of -339 for the current fiscal year.

ImmuPharma plc (LON:IMM - Get Free Report) shares shot up 17.2% during trading on Wednesday . The stock traded as high as GBX 15.15 ($0.20) and last traded at GBX 13.04 ($0.18). 47,707,926 shares were traded during mid-day trading, an increase of 514% from the average session volume of 7,768,032 shares. The stock had previously closed at GBX 11.13 ($0.15).

ImmuPharma Stock Up 18.7%

The company has a 50 day moving average of GBX 2.55 and a 200-day moving average of GBX 2.76. The stock has a market capitalization of £65.96 million, a P/E ratio of -1,483.15 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Equities analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.